The Tenth Circuit said that, to this point, the courtroom has not adopted a benchmark proportion for attorneys’ charges and declines to take action—as an alternative, the courtroom mentioned that awards in a spread of percentages could also be affordable.
The plaintiffs within the underlying case are shareholders in Array Biopharma. According to the opinion, these shareholders introduced a federal securities class motion declare in opposition to Array and its executives and alleged that the defendants made deliberate statements a few medical trial leading to important shareholder losses.
